Garutti Mattia, Griguolo Gaia, Botticelli Andrea, Buzzatti Giulia, De Angelis Carmine, Gerratana Lorenzo, Molinelli Chiara, Adamo Vincenzo, Bianchini Giampaolo, Biganzoli Laura, Curigliano Giuseppe, De Laurentiis Michelino, Fabi Alessandra, Frassoldati Antonio, Gennari Alessandra, Marchiò Caterina, Perrone Francesco, Viale Giuseppe, Zamagni Claudio, Zambelli Alberto, Del Mastro Lucia, De Placido Sabino, Guarneri Valentina, Marchetti Paolo, Puglisi Fabio
CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy.
Department of Surgery, Oncology and Gastroenterology, University of Padova, 35100 Padova, Italy.
Cancers (Basel). 2022 Apr 9;14(8):1898. doi: 10.3390/cancers14081898.
Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2-negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/HER2-negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2-negative early breast cancers.
乳腺癌是全球女性癌症相关发病和死亡的主要原因之一。在过去三十年中，随着优化辅助化疗和内分泌治疗的引入，激素受体阳性/人表皮生长因子受体2阴性乳腺癌的辅助治疗取得了多项进展。然而，基于个体评估乳腺癌复发风险仍然具有挑战性。IRIDE（乳腺癌高风险定义）工作组的成立旨在回顾文献证据，以综合当前预测激素阳性/人表皮生长因子受体2阴性早期乳腺癌复发的相关特征。一组乳腺癌专家参与确定临床、病理、形态和遗传因素。采用兰德共识方法来定义每个风险因素的相关性。在纳入的21项特征中，12项被认为是复发的相关风险因素。对于其中每一项，我们提供了共识声明以及关于支持性科学证据的相关评论。这项工作可能会指导临床医生对激素阳性/人表皮生长因子受体2阴性早期乳腺癌进行实际管理。
